Bayer, Regeneron Lose U.K. Patent Fight on Blockbuster Eye Drug

A potential blockbuster drug produced by Bayer AG and Regeneron Pharmaceuticals Inc. to treat a blindness-causing eye disorder infringes a patent held by Genentech Inc., a U.K. judge ruled.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.